Table 5.
Subjects clinical and laboratory information (before and after treatment).
| Nano-curcumin group | P value | Placebo group (n = 12) | P value | |||
|---|---|---|---|---|---|---|
| Before(n = 20) | After(n = 16) | After(n = 12) | Before(n = 20) | |||
| Fever | ||||||
| <37.3 °C | 1 (5%) | 10(62.5%) | <0.0001 | 4(33.33%) | 0(0%) | 0.003 |
| 37.3–38.0 °C | 9 (45%) | 6 (37.5%) | 7 (58.33%) | 8 (40%) | ||
| 38.1–39.0 °C | 7 (37%) | 0 (0%) | 1 (8.33%) | 7 (35%) | ||
| >39.0 °C | 4 (20%) | 0 (0%) | 0 (0%) | 5 (25%) | ||
| Cough | 12 (60%) | 2(12.5%) | <0.0001 | 6 (50%) | 11 (55%) | NS |
| Headache | 1 (5%) | 0(0%) | – | 0(0%) | 2 (10%) | – |
| Dyspnea | 5 (25%) | 1(6.25%) | <0.0001 | 1(8.33%) | 4 (20%) | 0.01 |
| White blood cell count, × 109/L | <0.0001 | NS | ||||
| <4 | 5 (25%) | 2 (12.5%) | 2 (16.66%) | 5 (25%) | ||
| 4–10 | 9 (45%) | 3 (18.75%) | 4 (33.33%) | 8 (40%) | ||
| >10 | 6 (30%) | 2(12.25%) | 6 (50%) | 7 (35%) | ||
| Lymphocyte count, × 109/L | <0.0001 | NS | ||||
| <1·0 | 13 (65%) | 4 (25%%) | 6 (50%) | 11 (55%) | ||
| ≥1·0 | 7 (35%) | 12 (75%%) | 6 (50%) | 9 (45%) | ||
| Platelet count, × 109/L | <0.0001 | 0.04 | ||||
| <100 | 11 (55%) | 6 (37.5%) | 5 (41.66%) | 11 (55%) | ||
| ≥100 | 9 (45%) | 10 (62.5%) | 7(58.33%) | 8 (40%) | ||
| Creatinine, μmol/L | 0.002 | NS | ||||
| ≤133 | 18 (90%) | 13 (81.25%) | 9 (75%) | 17 (85%) | ||
| >133 | 2 (10%) | 3 (18.75%) | 3 (25%) | 3 (15%) | ||
| Lactate dehydrogenase, U/L | <0.0001 | NS | ||||
| ≤245 | 13 (65%) | 15 (93.75%) | 7 (58.33%) | 13 (65%) | ||
| >245 | 7 (35%) | 1 (6.25%) | 5 (41.66%) | 7 (35%) | ||
| Bilateral involvement of chest radiographs | 19 (95%) | 10(62.5%) | <0.0001 | 9 (75%) | 19 (95%) | 0.002 |